Immunotherapy not highly effective in Ovarian cancers

Immunotherapy has made a significant difference to the lives of many cancer patients with Skin, Kidney, Bladder and Lung cancers.

But in ovarian cancer patients, the results of trials have been disappointing .

Data presented at ESMO ( European Society of Medical Oncology) shows that the Immunotherapy agents Pembrolizumab and Nivolumab do not make significant difference over and above chemotherapy.

A caveat though, patients who responded to Nivolumab has longer duration of response and Nivolumab was well tolerated. So this indicates a subset of patients may benefit from chemotherapy.

Disclaimer: Please note- This blog is NOT medical advice. This blog is purely for information only and do check the the sources where cited. Please consult your own doctor to discuss concerns and options relevant to you.

The views expressed in this blog represent the author’s views held at the time of drafting the blog and is likely to change overtime, particularly when new evidence comes to light. The blog is not necessarily endorsed by any organisation the author is associated with and views are not substitute for professional advice.